Provided by Tiger Fintech (Singapore) Pte. Ltd.

Keros Therapeutics, Inc.

14.44
-0.0300-0.21%
Post-market: 14.440.00000.00%18:26 EDT
Volume:351.44K
Turnover:5.08M
Market Cap:586.49M
PE:132.53
High:14.60
Open:14.36
Low:14.34
Close:14.47
Loading ...

Major Shareholder Sells Off Keros Therapeutics Stock!

TIPRANKS
·
25 Jun

Keros Therapeutics Hindered by KER-065 Concerns Despite 'Intriguing' Pipeline, BofA Says

MT Newswires Live
·
11 Jun

BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32

MT Newswires Live
·
10 Jun

Keros Therapeutics Cut to Neutral From Buy by B of A Securities

Dow Jones
·
10 Jun

Keros Therapeutics: Strategic Initiatives and Capital Return Signal Potential Upside

TIPRANKS
·
10 Jun

ADAR1 says Keros needs ‘fresh perspectives in the boardroom’

TIPRANKS
·
10 Jun

Adar1 Capital Management: Plans to Nominate New Directors for 2026 Annual Meeting

THOMSON REUTERS
·
10 Jun

Adar1 Capital Management : Calls for Return of $475 Mln to Stockholders by Q3 2025 for Keros Therapeutics

THOMSON REUTERS
·
10 Jun

Keros Therapeutics Inc Held Annual Stockholders Meeting Amid Shareholder Concerns

Reuters
·
10 Jun

Keros Therapeutics to return $375M in excess capital to stockholders

TIPRANKS
·
09 Jun

Keros Announces Return of $375 Million in Excess Capital to Stockholders

THOMSON REUTERS
·
09 Jun

Keros Therapeutics CEO to Speak at Healthcare Conference

TIPRANKS
·
07 Jun

Guggenheim Sticks to Their Hold Rating for Keros Therapeutics (KROS)

TIPRANKS
·
30 May

Keros Therapeutics (KROS) Gets a Buy from Scotiabank

TIPRANKS
·
30 May

William Blair Sticks to Their Hold Rating for Keros Therapeutics (KROS)

TIPRANKS
·
30 May

BofA says Keros cost reduction ‘disappoints,’ still sees reasons to like story

TIPRANKS
·
30 May

BRIEF-Keros Therapeutics Announces Tropos Topline Data And Corporate Restructuring

Reuters
·
29 May

Keros Cutting 45% of Staff, Ending Development of Cibotercept in PAH

Dow Jones
·
29 May

Keros Therapeutics Announces Tropos Topline Data and Corporate Restructuring

THOMSON REUTERS
·
29 May

Keros Therapeutics Inc - Discontinues Development of Cibotercept in Pah

THOMSON REUTERS
·
29 May